TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include live… Read more
TaiwanJ Pharmaceuticals Co., Ltd. (6549) - Net Assets
Latest net assets as of June 2025: NT$82.56 Million TWD
Based on the latest financial reports, TaiwanJ Pharmaceuticals Co., Ltd. (6549) has net assets worth NT$82.56 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$88.15 Million) and total liabilities (NT$5.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$82.56 Million |
| % of Total Assets | 93.65% |
| Annual Growth Rate | -8.92% |
| 5-Year Change | -45.97% |
| 10-Year Change | N/A |
| Growth Volatility | 32.38 |
TaiwanJ Pharmaceuticals Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how TaiwanJ Pharmaceuticals Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TaiwanJ Pharmaceuticals Co., Ltd. (2019–2024)
The table below shows the annual net assets of TaiwanJ Pharmaceuticals Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$95.05 Million | +42.00% |
| 2023-12-31 | NT$66.94 Million | -6.51% |
| 2022-12-31 | NT$71.60 Million | -56.20% |
| 2021-12-31 | NT$163.48 Million | -7.07% |
| 2020-12-31 | NT$175.92 Million | +16.00% |
| 2019-12-31 | NT$151.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TaiwanJ Pharmaceuticals Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19776100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$801.22 Million | 842.92% |
| Other Comprehensive Income | NT$2.33 Million | 2.45% |
| Other Components | NT$95.00K | 0.10% |
| Total Equity | NT$95.05 Million | 100.00% |
TaiwanJ Pharmaceuticals Co., Ltd. Competitors by Market Cap
The table below lists competitors of TaiwanJ Pharmaceuticals Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Superdong Fast Ferry Kien Giang JSC
VN:SKG
|
$16.40 Million |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
$16.40 Million |
|
4C Group AB
ST:4C
|
$16.40 Million |
|
Star Media Group Bhd
KLSE:6084
|
$16.40 Million |
|
The Caldwell Partners International Inc
OTCQX:CWLPF
|
$16.39 Million |
|
Sievi Capital Plc
F:WE3
|
$16.39 Million |
|
Orvana Minerals Corp
PINK:ORVMF
|
$16.39 Million |
|
NSE SA
PA:ALNSE
|
$16.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TaiwanJ Pharmaceuticals Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 66,940,000 to 95,053,000, a change of 28,113,000 (42.0%).
- Net loss of 22,341,000 reduced equity.
- New share issuances of 50,000,000 increased equity.
- Other comprehensive income increased equity by 2,330,000.
- Other factors decreased equity by 1,876,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-22.34 Million | -23.5% |
| Share Issuances | NT$50.00 Million | +52.6% |
| Other Comprehensive Income | NT$2.33 Million | +2.45% |
| Other Changes | NT$-1.88 Million | -1.97% |
| Total Change | NT$- | 42.00% |
Book Value vs Market Value Analysis
This analysis compares TaiwanJ Pharmaceuticals Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.40x to 6.03x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$2.21 | NT$7.49 | x |
| 2020-12-31 | NT$2.48 | NT$7.49 | x |
| 2021-12-31 | NT$2.18 | NT$7.49 | x |
| 2022-12-31 | NT$0.95 | NT$7.49 | x |
| 2023-12-31 | NT$0.89 | NT$7.49 | x |
| 2024-12-31 | NT$1.24 | NT$7.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TaiwanJ Pharmaceuticals Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-23.50%) is above the historical average (-32.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -3.35% | -8.24% | 0.39x | 1.05x | NT$-20.25 Million |
| 2020 | -24.13% | 0.00% | 0.00x | 1.04x | NT$-60.05 Million |
| 2021 | -7.60% | -56.32% | 0.13x | 1.04x | NT$-28.77 Million |
| 2022 | -129.14% | -602.19% | 0.19x | 1.11x | NT$-99.63 Million |
| 2023 | -9.03% | -26.59% | 0.31x | 1.10x | NT$-12.74 Million |
| 2024 | -23.50% | 0.00% | 0.00x | 1.06x | NT$-31.85 Million |
Industry Comparison
This section compares TaiwanJ Pharmaceuticals Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TaiwanJ Pharmaceuticals Co., Ltd. (6549) | NT$82.56 Million | -3.35% | 0.07x | $16.39 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |